
US Democrats are still trying to pass a bill that would cap diabetes patients’ out-of-pocket insulin expenses in the country.
Should it pass, the legislation could impact insulin makers supplying the US, including Novo Nordisk, Eli Lilly, and Sanofi, which are behind 90% of insulin sales in the US.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app